CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

DOTTI

estradiol· ingredient estradiol· ESTRADIOL .025 mg/d; ESTRADIOL .0375 mg/d; ESTRADIOL .05 mg/d; ESTRADIOL .075 mg/d
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$7.65
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other estradiol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Estradiol$0.06599−$7.59
Estradiol$0.06599−$7.59
ESTRACE$0.38605−$7.27
ABIGALE$0.69593−$6.96
Mimvey$0.70126−$6.95
DIVIGEL$1.47−$6.18
ELESTRIN$3.52−$4.13
Bijuva$8.69+$1.04

Medicare Part D coverage · CY2026

On 310 plan formularies · typical tier 3
Prior auth 4% · Step therapy 0% · Quantity limit 56% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.